Induction of tolerance and suppression of rejection by transfer of immature hepatic dendritic cells.

(1)大鼠同种异体小肠移植物静脉注射CTLA41g（100杯/头）7d获得免疫耐受。同种异体小肠移植在大鼠体内获得了较长的存活期（100 ~ 100天）。耐受大鼠血清IL-4和IL-10水平升高，表明Th2型抗异体免疫反应有利于同种异体移植组织的存活。(2)静脉注射CTLA4Ig对大鼠同种异体肾移植也能产生免疫耐受。然而，注射同种异体脾树突状细胞或ctla4ig处理的树突状细胞不能诱导同种异体肾移植耐受或长时间存活。(3)制备了含CTLA4Ig的腺病毒载体，可用于体内和体外生产CTLA4Ig。

(1) Immunological tolerance was achieved by intravenous injection of CTLA41g (100mug/head) for 7days in rat small bowel allografts. Long survival (>100days) of allografed small bowel was achieved in rat system. Increased serum levels of IL-4 and IL-10 were defected in tolerant rats, indicating that the Th2 type anti-allogeneic immune response favors the survival of allografted tissue.(2) Immunological tolerance was also achieved by intravenous injection of CTLA4Ig in rat kidney allografts. However, injection of allogeneic splenic dendritic cells or CTLA4Ig-treated dendritic cells failed to induce tolerance or long survival of allografted Kidney.(3) We generated adenovirus vectors containig CTLA4Ig, which can be used for the in vivo and in vitro production of CTLA4Ig.